http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 21 Aug 2026 14:32:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+20++Filed+by%3A+SCULLY+WILLIAM+P/26960812.html si-local-file:///var/storage/secattach/20260821/26960812.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+20++Filed+by%3A+SCULLY+WILLIAM+P/26960812.html Fri, 21 Aug 2026 14:32:00 -0400 O.14405960 PRTA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+20++Filed+by%3A+SCULLY+WILLIAM+P/26960812.html si-local-file:///var/storage/secattach/20260821/26960812.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+20++Filed+by%3A+SCULLY+WILLIAM+P/26960812.html Fri, 21 Aug 2026 14:32:00 -0400 O.14405960 PRTA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PROTHENA+CORP+PUBLIC+++++++++++++++++++Filed+by%3A+Fennell+Todd+W./26948408.html si-local-file:///var/storage/secattach/20260819/26948408.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PROTHENA+CORP+PUBLIC+++++++++++++++++++Filed+by%3A+Fennell+Todd+W./26948408.html Wed, 19 Aug 2026 10:19:00 -0400 O.14405960 PRTA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PROTHENA+CORP+PUBLIC+++++++++++++++++++Filed+by%3A+Fennell+Todd+W./26948408.html si-local-file:///var/storage/secattach/20260819/26948408.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PROTHENA+CORP+PUBLIC+++++++++++++++++++Filed+by%3A+Fennell+Todd+W./26948408.html Wed, 19 Aug 2026 10:19:00 -0400 O.14405960 PRTA http://www.streetinsider.com/SEC+Filings/Form++3++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+18++Filed+by%3A+Fennell+Todd+W./26944502.html si-local-file:///var/storage/secattach/20260818/26944502.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+18++Filed+by%3A+Fennell+Todd+W./26944502.html Tue, 18 Aug 2026 16:17:00 -0400 O.14405960 PRTA http://www.streetinsider.com/SEC+Filings/Form++3++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+18++Filed+by%3A+Fennell+Todd+W./26944502.html si-local-file:///var/storage/secattach/20260818/26944502.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+18++Filed+by%3A+Fennell+Todd+W./26944502.html Tue, 18 Aug 2026 16:17:00 -0400 O.14405960 PRTA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+18++Filed+by%3A+SCULLY+WILLIAM+P/26944110.html si-local-file:///var/storage/secattach/20260818/26944110.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+18++Filed+by%3A+SCULLY+WILLIAM+P/26944110.html Tue, 18 Aug 2026 16:03:00 -0400 O.14405960 PRTA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+18++Filed+by%3A+SCULLY+WILLIAM+P/26944110.html si-local-file:///var/storage/secattach/20260818/26944110.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+18++Filed+by%3A+SCULLY+WILLIAM+P/26944110.html Tue, 18 Aug 2026 16:03:00 -0400 O.14405960 PRTA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PROTHENA+CORP+PUBLIC+++++++++++++++++++Filed+by%3A+Fennell+Todd+W./26925630.html si-local-file:///var/storage/secattach/20260814/26925630.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PROTHENA+CORP+PUBLIC+++++++++++++++++++Filed+by%3A+Fennell+Todd+W./26925630.html Fri, 14 Aug 2026 09:10:00 -0400 O.14405960 PRTA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PROTHENA+CORP+PUBLIC+++++++++++++++++++Filed+by%3A+Fennell+Todd+W./26925630.html si-local-file:///var/storage/secattach/20260814/26925630.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PROTHENA+CORP+PUBLIC+++++++++++++++++++Filed+by%3A+Fennell+Todd+W./26925630.html Fri, 14 Aug 2026 09:10:00 -0400 O.14405960 PRTA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+10++Filed+by%3A+SCULLY+WILLIAM+P/26905712.html si-local-file:///var/storage/secattach/20260811/26905712.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+10++Filed+by%3A+SCULLY+WILLIAM+P/26905712.html Tue, 11 Aug 2026 16:08:00 -0400 O.14405960 PRTA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+10++Filed+by%3A+SCULLY+WILLIAM+P/26905712.html si-local-file:///var/storage/secattach/20260811/26905712.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+10++Filed+by%3A+SCULLY+WILLIAM+P/26905712.html Tue, 11 Aug 2026 16:08:00 -0400 O.14405960 PRTA http://www.streetinsider.com/SEC+Filings/Form++3++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+06++Filed+by%3A+Fennell+Todd+W./26902992.html si-local-file:///var/storage/secattach/20260811/26902992.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+06++Filed+by%3A+Fennell+Todd+W./26902992.html Tue, 11 Aug 2026 09:38:00 -0400 O.14405960 PRTA http://www.streetinsider.com/SEC+Filings/Form++3++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+06++Filed+by%3A+Fennell+Todd+W./26902992.html si-local-file:///var/storage/secattach/20260811/26902992.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+06++Filed+by%3A+Fennell+Todd+W./26902992.html Tue, 11 Aug 2026 09:38:00 -0400 O.14405960 PRTA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+07++Filed+by%3A+SCULLY+WILLIAM+P/26897336.html si-local-file:///var/storage/secattach/20260810/26897336.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+07++Filed+by%3A+SCULLY+WILLIAM+P/26897336.html Mon, 10 Aug 2026 15:25:00 -0400 O.14405960 PRTA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+07++Filed+by%3A+SCULLY+WILLIAM+P/26897336.html si-local-file:///var/storage/secattach/20260810/26897336.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+07++Filed+by%3A+SCULLY+WILLIAM+P/26897336.html Mon, 10 Aug 2026 15:25:00 -0400 O.14405960 PRTA http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PROTHENA+CORP+PUBLIC++++++For%3A+Jun+30/26884454.html si-local-file:///var/storage/secattach/20260806/26884454.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PROTHENA+CORP+PUBLIC++++++For%3A+Jun+30/26884454.html Thu, 06 Aug 2026 16:20:00 -0400 O.14405960 PRTA http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PROTHENA+CORP+PUBLIC++++++For%3A+Jun+30/26884454.html si-local-file:///var/storage/secattach/20260806/26884454.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PROTHENA+CORP+PUBLIC++++++For%3A+Jun+30/26884454.html Thu, 06 Aug 2026 16:20:00 -0400 O.14405960 PRTA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+06/26884296.html si-local-file:///var/storage/secattach/20260806/26884296.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+06/26884296.html Thu, 06 Aug 2026 16:17:00 -0400 O.14405960 PRTA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+06/26884296.html si-local-file:///var/storage/secattach/20260806/26884296.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PROTHENA+CORP+PUBLIC++++++For%3A+Aug+06/26884296.html Thu, 06 Aug 2026 16:17:00 -0400 O.14405960 PRTA http://www.streetinsider.com/Press+Releases/Prothena+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26883459.html <ul class="bwlistdisc"> <li> Net cash used in operating and investing activities was $25.7 million in the second quarter and net cash provided by operating and investing activities was $3.2 million for the first six months of 2026; quarter-end cash and restricted cash position was $289.1 million </li> <li> Guidance updated to include shares repurchased through July 30, 2026 and now expects to end the year with approximately $259 million (midpoint) in cash, cash equivalents and restricted cash </li> <li> Results from partner Roche evaluating prasinezumab in patients with early Parkinson’s disease from the Phase 2b PADOVA clinical trial published in <i>The Lancet</i> </li> <li> Multiple research collaborations with industry partners ongoing http://www.streetinsider.com/Press+Releases/Prothena+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26883459.html Thu, 06 Aug 2026 16:05:00 -0400 A.40718029 A.60012012 O.00071176 O.14405960 O.20847516 PRTA http://www.streetinsider.com/Press+Releases/Prothena+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26883459.html <ul class="bwlistdisc"> <li> Net cash used in operating and investing activities was $25.7 million in the second quarter and net cash provided by operating and investing activities was $3.2 million for the first six months of 2026; quarter-end cash and restricted cash position was $289.1 million </li> <li> Guidance updated to include shares repurchased through July 30, 2026 and now expects to end the year with approximately $259 million (midpoint) in cash, cash equivalents and restricted cash </li> <li> Results from partner Roche evaluating prasinezumab in patients with early Parkinson’s disease from the Phase 2b PADOVA clinical trial published in <i>The Lancet</i> </li> <li> Multiple research collaborations with industry partners ongoing http://www.streetinsider.com/Press+Releases/Prothena+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26883459.html Thu, 06 Aug 2026 16:05:00 -0400 A.40718029 A.60012012 O.00071176 O.14405960 O.20847516 PRTA http://www.streetinsider.com/Press+Releases/Prothena+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26883459.html <ul class="bwlistdisc"> <li> Net cash used in operating and investing activities was $25.7 million in the second quarter and net cash provided by operating and investing activities was $3.2 million for the first six months of 2026; quarter-end cash and restricted cash position was $289.1 million </li> <li> Guidance updated to include shares repurchased through July 30, 2026 and now expects to end the year with approximately $259 million (midpoint) in cash, cash equivalents and restricted cash </li> <li> Results from partner Roche evaluating prasinezumab in patients with early Parkinson’s disease from the Phase 2b PADOVA clinical trial published in <i>The Lancet</i> </li> <li> Multiple research collaborations with industry partners ongoing http://www.streetinsider.com/Press+Releases/Prothena+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26883459.html Thu, 06 Aug 2026 16:05:00 -0400 A.40718029 A.60012012 O.00071176 O.14405960 O.20847516 PRTA http://www.streetinsider.com/Press+Releases/Prothena+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26883459.html <ul class="bwlistdisc"> <li> Net cash used in operating and investing activities was $25.7 million in the second quarter and net cash provided by operating and investing activities was $3.2 million for the first six months of 2026; quarter-end cash and restricted cash position was $289.1 million </li> <li> Guidance updated to include shares repurchased through July 30, 2026 and now expects to end the year with approximately $259 million (midpoint) in cash, cash equivalents and restricted cash </li> <li> Results from partner Roche evaluating prasinezumab in patients with early Parkinson’s disease from the Phase 2b PADOVA clinical trial published in <i>The Lancet</i> </li> <li> Multiple research collaborations with industry partners ongoing http://www.streetinsider.com/Press+Releases/Prothena+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26883459.html Thu, 06 Aug 2026 16:05:00 -0400 A.40718029 A.60012012 O.00071176 O.14405960 O.20847516 PRTA http://www.streetinsider.com/Press+Releases/Prothena+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26883459.html <ul class="bwlistdisc"> <li> Net cash used in operating and investing activities was $25.7 million in the second quarter and net cash provided by operating and investing activities was $3.2 million for the first six months of 2026; quarter-end cash and restricted cash position was $289.1 million </li> <li> Guidance updated to include shares repurchased through July 30, 2026 and now expects to end the year with approximately $259 million (midpoint) in cash, cash equivalents and restricted cash </li> <li> Results from partner Roche evaluating prasinezumab in patients with early Parkinson’s disease from the Phase 2b PADOVA clinical trial published in <i>The Lancet</i> </li> <li> Multiple research collaborations with industry partners ongoing http://www.streetinsider.com/Press+Releases/Prothena+Reports+Second+Quarter+2026+Financial+Results+and+Business+Highlights/26883459.html Thu, 06 Aug 2026 16:05:00 -0400 A.40718029 A.60012012 O.00071176 O.14405960 O.20847516 PRTA